Advertisement

Identifying and enriching platelet-producing human stem cell–derived megakaryocytes using factor V uptake

Xiuli Sim, Danuta Jarocha, Vincent Hayes, Hayley A. Hanby, Michael S. Marks, Rodney M. Camire, Deborah L. French, Mortimer Poncz and Paul Gadue

Key Points

  • Describe human MK populations representing distinct developmental stages within a heterogeneous culture.

  • FV uptake identifies cultured MKs ready to release platelets upon infusion into mice.

Publisher's Note: There is an Inside Blood Commentary on this article in this issue.

Abstract

Stem cell–derived platelets have the potential to replace donor platelets for transfusion. Defining the platelet-producing megakaryocytes (MKs) within the heterogeneous MK culture may help to optimize the in vitro generation of platelets. Using 2 human stem cell models of megakaryopoiesis, we identified novel MK populations corresponding to distinct maturation stages. An immature, low granular (LG) MK pool (defined by side scatter on flow cytometry) gives rise to a mature high granular (HG) pool, which then becomes damaged by apoptosis and glycoprotein Ib α chain (CD42b) shedding. We define an undamaged HG/CD42b+ MK subpopulation, which endocytoses fluorescently labeled coagulation factor V (FV) from the media into α-granules and releases functional FV+CD42b+ human platelet-like particles in vitro and when infused into immunodeficient mice. Importantly, these FV+ particles have the same size distribution as infused human donor platelets and are preferentially incorporated into clots after laser injury. Using drugs to protect HG MKs from apoptosis and CD42b shedding, we also demonstrate that apoptosis precedes CD42b shedding and that apoptosis inhibition enriches the FV+ HG/CD42b+ MKs, leading to increased platelet yield in vivo, but not in vitro. These studies identify a transition between distinct MK populations in vitro, including one that is primed for platelet release. Technologies to optimize and select these platelet-ready MKs may be important to efficiently generate functional platelets from in vitro–grown MKs.

  • Submitted January 5, 2017.
  • Accepted April 14, 2017.
View Full Text